In Vitro Screening with PDO and PDXO
CrownBio has entered into an exclusive partnership with Hubrecht Organoid Technology (HUB) to provide preclinical drug development and validation services using the HUB organoid technology and HUB tumor organoid biobank.
CrownBio’s HUB Organoid Services are expected to be available by late 2019! This highly translational in vitro screening platform includes the development of patient-derived organoids (PDO) and PDX-derived organoids from CrownBio’s extensive patient-derived xenograft (PDX) collection.
Models Currently In Development
HUB’s adult stem cell-derived organoids, originally developed in the Clevers Lab are generated using highly standardized, proprietary culture methods. The organoids faithfully recapitulate tumors in patients and are extensively characterized by pathology, genomics, and sensitivity to known and experimental drugs.
Help Us Build The Optimum Service Portfolio
Your input will help us to build shape the most useful preclinical platform, and prioritise model development. We greatly appreciate your participation in our quick 2 minute survey.
Join the Organoid Mailing List
To receive the most up to date information on CrownBio's Organoid Service development, simply complete the the form to the right to receive the latest organoid information, news and content.